Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2+/HR+ Breast Cancer”

545 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 545 results

Not applicableActive Not RecruitingNCT04767594
What this trial is testing

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Who this might be right for
Breast Neoplasms
Pfizer 1,409
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06750848
What this trial is testing

Chidamide Combined With Angiogenesis Inhibitors and Fulvestrant for Advanced HR-positive, HER2-negative Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jundong Wu 48
Testing effectiveness (Phase 2)Study completedNCT04224272
What this trial is testing

ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Who this might be right for
HER2+/HR+ Breast Cancer
Jazz Pharmaceuticals 51
Not applicableStudy completedNCT07052734
What this trial is testing

Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients

Who this might be right for
Breast Cancer
Sun Yat-sen University 2,843
Testing effectiveness (Phase 2)Looking for participantsNCT05728268
What this trial is testing

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Who this might be right for
Breast Cancer
Shantou Central Hospital 64
Testing effectiveness (Phase 2)Study completedNCT05159778
What this trial is testing

Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)

Who this might be right for
Malignant Neoplasm of Breast
HiberCell, Inc. 26
Post-approval studies (Phase 4)Ended earlyNCT04657679
What this trial is testing

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

Who this might be right for
Breast Cancer
Georgetown University 21
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Not applicableStudy completedNCT02536625
What this trial is testing

Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

Who this might be right for
Breast Cancer
Centre Leon Berard 62
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06339281
What this trial is testing

Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Li Huiping 68
Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Large-scale testing (Phase 3)Active Not RecruitingNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Not applicableStudy completedNCT05505175
What this trial is testing

Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC

Who this might be right for
Breast CancerBreast Carcinoma
Pfizer 120
Testing effectiveness (Phase 2)Ended earlyNCT05966584
What this trial is testing

Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Memorial Sloan Kettering Cancer Center 1
Testing effectiveness (Phase 2)UnknownNCT04791384
What this trial is testing

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Who this might be right for
Breast Cancer
Criterium, Inc. 44
Not applicableLooking for participantsNCT06050109
What this trial is testing

The Benefits of Continued Use of Ovarian Function Suppression After 5 Years

Who this might be right for
Breast Cancer FemaleEndocrine Therapy
Hongmei Zheng, PhD 1,200
Testing effectiveness (Phase 2)WithdrawnNCT02853071
What this trial is testing

Efficacy and Safety of Estracyt® in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Centre Hospitalier Universitaire de Besancon
Large-scale testing (Phase 3)UnknownNCT05439499
What this trial is testing

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerFemale Breast Cancer
Ahon Pharmaceutical Co., Ltd. 434
Load More Results